- Home
- JKHY vs PODD Comparison
JKHY vs PODD Comparison
Compare JKHY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | PODD |
|---|---|---|
| Founded | 1976 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.2B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | JKHY | PODD |
|---|---|---|
| Price | $149.46 | $139.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | $197.25 | ★ $341.48 |
| AVG Volume (30 Days) | 889.9K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 11.86 | N/A |
| EPS | ★ 6.98 | 2.67 |
| Revenue | $1,536,603,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $8.03 | $24.55 |
| Revenue Next Year | $6.39 | $19.18 |
| P/E Ratio | ★ $21.71 | $52.63 |
| Revenue Growth | 7.37 | ★ 30.73 |
| 52 Week Low | $121.04 | $126.40 |
| 52 Week High | $193.39 | $354.88 |
Technical Indicators
Market Signals| Indicator | JKHY | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 44.98 |
| Support Level | $146.96 | $139.67 |
| Resistance Level | $157.59 | $153.33 |
| Average True Range (ATR) | 4.53 | 4.47 |
| MACD | -1.87 | 0.39 |
| Stochastic Oscillator | 3.07 | 45.66 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.